PureTech Health (LON:PRTC) Stock Price Up 9.1% - Here's Why

Key Points

• PureTech Health stock surged 9.1% in mid-day trading, reaching a high of GBX 116.80 ($1.58), up from a previous close of GBX 106.40 ($1.44).
• Insider Bharatt Chowrira purchased 167,739 shares at an average price of GBX 1 per share, increasing insider ownership to 13.13%.
• The company is a clinical-stage biopharma firm focused on developing drugs for diseases affecting the nervous, gastrointestinal, and immune systems.

PureTech Health plc (LON:PRTC - Get Free Report) shot up 9.1% on Friday . The stock traded as high as GBX 116.80 ($1.58) and last traded at GBX 116.04 ($1.57). 866,820 shares traded hands during trading, an increase of 18% from the average session volume of 736,782 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Stock Up 4.2%

The firm has a 50 day simple moving average of GBX 129.31 and a two-hundred day simple moving average of GBX 129.65. The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The stock has a market capitalization of £303.07 million, a P/E ratio of 737.65 and a beta of 1.02.

Insider Activity at PureTech Health

In other news, insider Bharatt Chowrira purchased 167,739 shares of the company's stock in a transaction dated Thursday, July 3rd. The stock was bought at an average cost of GBX 1 per share, for a total transaction of £1,677.39. Insiders own 13.13% of the company's stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.